Increased expression of another ARF6 GEF, EFA6A, has been shown in glioma and linked to promoting invasiveness [53], while EFA6B (in breast cancer) and EFA6R (in ovarian cancer) have been shown to play possible roles as tumour suppressors [54, 55]. Here, PSD is linked to breast carcinoma.